Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > below 8 soon

<< Previous

Bullboard Posts

Next >>

Comment by Arrakis37on Oct 14, 2020 12:57pm

105 Views

Post# 31714485

RE:RE:below 8 soon

Like someone said before : "There something rotten in the state of Denmark."

stockbuphoon wrote: Edrose, you know Boehringer was clearly doing due diligence in Laval in mid 2018 but PLI could not close a deal when there was a deal to be made. No excuse. Efficacy in 6 organs on 4050 - something very wrong if this drug ultimately becomes an overwhelming success. Galbraith and Best should be held to account for not getting Laurin to make a deal and not moving 4050 trials into a placebo controlled trial or MAD study in 2016/17. No excuse for spending $120M a year and not doing Phase 1 multiple ascending dosage trials.

edrose wrote: so much potential re 4050 ,plasma proteins small molecule and they tell not one drog company was interested in prometic over pass few years